- |||||||||| Trial primary completion date: Individualized Stereotactic Body Radiotherapy of Liver Metastases (clinicaltrials.gov) - Jul 13, 2017
P2, N=92, Active, not recruiting, Enrolling by invitation --> Active, not recruiting | N=500 --> 241 | Trial primary completion date: Sep 2019 --> Jul 2017 Trial primary completion date: Jan 2017 --> Jan 2016
- |||||||||| Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Trial completion, Trial primary completion date, Metastases: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Jul 11, 2017 P2, N=252, Completed, N=80 --> 29 | Recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Mar 2013 Active, not recruiting --> Completed | Trial primary completion date: Sep 2017 --> Mar 2017
- |||||||||| sorafenib / Generic mfg.
Trial primary completion date: Sorafenib for Hepatopulmonary Syndrome (clinicaltrials.gov) - Jul 6, 2017 P2, N=30, Recruiting, Trial primary completion date: May 2017 --> May 2018 Trial primary completion date: Jun 2017 --> Jun 2018
- |||||||||| oxaliplatin / Generic mfg., erlotinib / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer (clinicaltrials.gov) - Jul 2, 2017 P1, N=28, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment change, Trial withdrawal, Surgery: Radiolabeled Glass Beads (TheraSphere (clinicaltrials.gov) - Jun 26, 2017 P2, N=0, Withdrawn, Trial primary completion date: Jul 2017 --> Jul 2018 N=500 --> 0 | Recruiting --> Withdrawn
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Trial completion, Enrollment change, Trial primary completion date, Metastases: Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - May 25, 2017 P1, N=7, Completed, Trial primary completion date: Jul 2017 --> Dec 2017 Active, not recruiting --> Completed | N=70 --> 7 | Trial primary completion date: Jun 2016 --> Nov 2010
- |||||||||| Enrollment change, Trial termination, Trial primary completion date: INFECIR2: The INFECIR-2 Albumin Prevention Study (clinicaltrials.gov) - May 18, 2017
P4, N=136, Terminated, No Longer Available --> Completed | Phase classification: PN/A --> P4 N=512 --> 136 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Dec 2016; Low recruitment rate and expiration of the study drug
- |||||||||| Enrollment change: HepART-RCT: Hepatitis C Alcohol Reduction Treatment (clinicaltrials.gov) - May 17, 2017
P=N/A, N=279, Recruiting, N=512 --> 136 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Dec 2016; Low recruitment rate and expiration of the study drug N=230 --> 279
- |||||||||| Enrollment closed, Trial primary completion date: Gilead Sustained Virologic Response (SVR) Registry (clinicaltrials.gov) - May 16, 2017
P=N/A, N=6580, Active, not recruiting, Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2020 --> Jan 2020 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2020 --> Jan 2020
- |||||||||| Tyzeka (telbivudine) / Novartis
Enrollment closed, Combination therapy: TDF and LdT in Immune-tolerant CHB Patients Awaiting Assisted Reproduction (clinicaltrials.gov) - May 16, 2017 P1/2, N=120, Active, not recruiting, Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2020 --> Jan 2020 Enrolling by invitation --> Active, not recruiting
- |||||||||| Enrollment change, Trial termination, Trial primary completion date: Immune Response to Hepatitis B Virus Booster Vaccination After 20-23 Years (clinicaltrials.gov) - May 15, 2017
P=N/A, N=9, Terminated, Enrolling by invitation --> Active, not recruiting N=50 --> 9 | Recruiting --> Terminated | Trial primary completion date: Dec 2014 --> Dec 2015; Participants were not recruited promptly
- |||||||||| Taxoprexin (DHA-paclitaxel) / Daiichi Sankyo
Enrollment change, Trial termination, Metastases: Taxoprexin (clinicaltrials.gov) - May 10, 2017 P2, N=13, Terminated, N=700 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2017 --> Jan 2017 N=60 --> 13 | Completed --> Terminated; Sponsor suspended development of the drug on September 3, 2008.
- |||||||||| OPB-111077 / Otsuka
Enrollment change, Trial termination, Trial primary completion date, Metastases: A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma) (clinicaltrials.gov) - May 9, 2017 P1, N=33, Terminated, Recruiting --> Active, not recruiting | N=150 --> 111 | Trial primary completion date: Mar 2017 --> Dec 2018 N=48 --> 33 | Recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Jun 2016; Company decision
|